title: 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.
abstract: 1,3-Disubstituted ureas possessing a piperidyl moiety have been synthesized to investigate their structure-activity relationships as inhibitors of the human and murine soluble epoxide hydrolase (sEH). Oral administration of 13 1-aryl-3-(1-acylpiperidin-4-yl)urea inhibitors in mice revealed substantial improvements in pharmacokinetic parameters over previously reported 1-adamantylurea based inhibitors. For example, 1-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (52) showed a 7-fold increase in potency, a 65-fold increase in C(max), and a 3300-fold increase in AUC over its adamantane analogue 1-(1-adamantyl)-3-(1-propionylpiperidin-4-yl)urea (2). This novel sEH inhibitor showed a 1000-fold increase in potency when compared to morphine by reducing hyperalgesia as measured by mechanical withdrawal threshold using the in vivo carrageenan induced inflammatory pain model.
authors.affiliation: Department of Entomology and University of California Davis Cancer Center, University of California, One Shields Avenue, Davis, California 95616, USA.
authors.forename: Tristan E
authors.initials: TE
authors.lastname: Rose
authors.forename: Christophe
authors.initials: C
authors.lastname: Morisseau
authors.forename: Jun-Yan
authors.initials: JY
authors.lastname: Liu
authors.forename: Bora
authors.initials: B
authors.lastname: Inceoglu
authors.forename: Paul D
authors.initials: PD
authors.lastname: Jones
authors.forename: James R
authors.initials: JR
authors.lastname: Sanborn
authors.forename: Bruce D
authors.initials: BD
authors.lastname: Hammock
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology; D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D002351:Carrageenan; D004851:Epoxide Hydrolases / Q000037:antagonists & inhibitors*; D006801:Humans; D008297:Male; D051379:Mice; D009020:Morphine / Q000494:pharmacology; D010146:Pain / Q000139:chemically induced / Q000188:drug therapy*; D010880:Piperidines / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012995:Solubility; D013329:Structure-Activity Relationship; D014508:Urea / Q000031:analogs & derivatives* / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology
chemical_list: D000701:Analgesics, Opioid; D000894:Anti-Inflammatory Agents, Non-Steroidal; D010880:Piperidines; D009020:Morphine; D014508:Urea; D002351:Carrageenan; D004851:Epoxide Hydrolases; D000218:Adamantane
references.citation: Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):8849-54
references.pmid: 10430859
references.citation: Nat Med. 1997 May;3(5):562-6
references.pmid: 9142128
references.citation: J Med Chem. 2009 Aug 27;52(16):5009-12
references.pmid: 19645482
references.citation: Congest Heart Fail. 2008 Jul-Aug;14(4):219-24
references.pmid: 18780476
references.citation: Future Neurol. 2009 Mar 1;4(2):179-199
references.pmid: 19779591
references.citation: J Med Chem. 2005 May 19;48(10):3621-9
references.pmid: 15887969
references.citation: Bioorg Med Chem Lett. 2010 Jan 15;20(2):571-5
references.pmid: 19969453
references.citation: Bioorg Med Chem. 2003 Sep 15;11(19):4225-34
references.pmid: 12951153
references.citation: Circ Res. 2000 Nov 24;87(11):992-8
references.pmid: 11090543
references.citation: Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18901-6
references.pmid: 19028872
references.citation: Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9772-7
references.pmid: 15994227
references.citation: Curr Top Med Chem. 2007;7(14):1379-93
references.pmid: 17692027
references.citation: Auton Autacoid Pharmacol. 2009 Jan;29(1-2):33-41
references.pmid: 19302554
references.citation: Annu Rev Pharmacol Toxicol. 2005;45:311-33
references.pmid: 15822179
references.citation: Prog Lipid Res. 2004 Jan;43(1):55-90
references.pmid: 14636671
references.citation: Bioorg Med Chem Lett. 2010 Jun 15;20(12):3703-7
references.pmid: 20472432
references.citation: Nat Rev Drug Discov. 2009 Oct;8(10):794-805
references.pmid: 19794443
references.citation: Am J Physiol Renal Physiol. 2005 Sep;289(3):F496-503
references.pmid: 16093425
references.citation: Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):564-9
references.pmid: 19126686
references.citation: J Med Chem. 2009 Oct 8;52(19):5880-95
references.pmid: 19746975
references.citation: Arch Biochem Biophys. 1993 Aug 15;305(1):197-201
references.pmid: 8342951
references.citation: J Biol Chem. 1993 Aug 15;268(23):17628-33
references.pmid: 8349642
references.citation: Bioorg Med Chem Lett. 2006 Oct 1;16(19):5212-6
references.pmid: 16870439
references.citation: Bioorg Med Chem Lett. 2009 Apr 15;19(8):2354-9
references.pmid: 19303288
references.citation: Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18733-8
references.pmid: 17130447
references.citation: Expert Opin Ther Pat. 2010 Jul;20(7):941-56
references.pmid: 20429668
references.citation: Curr Top Med Chem. 2009;9(5):452-63
references.pmid: 19519461
references.citation: Eur J Pharm Sci. 2010 Jun 14;40(3):222-38
references.pmid: 20359531
references.citation: Curr Atheroscler Rep. 2010 May;12(3):174-83
references.pmid: 20425256
references.citation: Anal Chim Acta. 2006 Feb 10;559(1):37-44
references.pmid: 16636700
references.citation: Curr Opin Investig Drugs. 2009 Mar;10(3):253-8
references.pmid: 19333883
references.citation: J Mol Cell Cardiol. 2009 Jun;46(6):867-75
references.pmid: 19285984
references.citation: Bioorg Med Chem Lett. 2009 Feb 15;19(4):1066-70
references.pmid: 19168352
references.citation: Anal Biochem. 1988 Feb 15;169(1):71-80
references.pmid: 3369689
references.citation: Bioorg Med Chem Lett. 2009 Sep 15;19(18):5314-20
references.pmid: 19682899
references.citation: Recent Pat Cardiovasc Drug Discov. 2006 Jan;1(1):67-72
references.pmid: 18221075
references.citation: Anal Biochem. 2005 Aug 1;343(1):66-75
references.pmid: 15963942
references.citation: Bioorg Med Chem Lett. 2009 Aug 1;19(15):4259-63
references.pmid: 19520575
references.citation: Biochem Pharmacol. 2002 May 1;63(9):1599-608
references.pmid: 12007563
references.citation: Bioorg Med Chem Lett. 2006 Nov 15;16(22):5773-7
references.pmid: 16949285
references.citation: Br J Pharmacol. 2009 Jan;156(2):284-96
references.pmid: 19154430
references.citation: J Med Chem. 2006 May 4;49(9):2829-37
references.pmid: 16640344
references.citation: Mol Cancer Ther. 2009 Aug;8(8):2193-203
references.pmid: 19671760
references.citation: J Med Chem. 2003 Mar 13;46(6):1066-80
references.pmid: 12620084
references.citation: J Cardiovasc Pharmacol. 2007 Sep;50(3):225-37
references.pmid: 17878749
references.citation: J Med Chem. 2007 Aug 9;50(16):3825-40
references.pmid: 17616115
references.citation: J Org Chem. 1996 May 31;61(11):3929-3934
references.pmid: 11667260